Alnylam Pharmaceuticals, Inc.
ALNY · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Alnylam Pharmaceuticals, Inc. at a glance
In FY2025, Alnylam Pharmaceuticals, Inc. reported revenue of USD 3,713,937 thousands, EBITDA of USD 561,941 thousands, EBITDA margin of 15.1%.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 2,248,243 | 3,713,937 | |||
| EBITDA | -103,358 | 561,941 | |||
| EBITDA margin | -4.6% | 15.1% | |||
| Free cash flow | -42,589 | 465,383 |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas